

# Rosario Mazzola

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3754739/publications.pdf>

Version: 2024-02-01

126  
papers

2,321  
citations

218381

26  
h-index

315357

38  
g-index

132  
all docs

132  
docs citations

132  
times ranked

2571  
citing authors

#	ARTICLE	IF	CITATIONS
1	Efficacy of stereotactic body radiotherapy in oligorecurrent and in oligoprogressive prostate cancer: new evidence from a multicentric study. <i>British Journal of Cancer</i> , 2017, 116, 1520-1525.	2.9	121
2	Linac-based VMAT radiosurgery for multiple brain lesions: comparison between a conventional multi-isocenter approach and a new dedicated mono-isocenter technique. <i>Radiation Oncology</i> , 2018, 13, 38.	1.2	117
3	1.5%T MR-guided and daily adapted SBRT for prostate cancer: feasibility, preliminary clinical tolerability, quality of life and patient-reported outcomes during treatment. <i>Radiation Oncology</i> , 2020, 15, 69.	1.2	94
4	Metastasis-directed stereotactic radiotherapy for oligoprogressive castration-resistant prostate cancer: a multicenter study. <i>World Journal of Urology</i> , 2019, 37, 2631-2637.	1.2	69
5	Metastasis-directed Therapy (SBRT) Guided by PET-CT 18F-CHOLINE Versus PET-CT 68Ga-PSMA in Castration-sensitive Oligorecurrent Prostate Cancer: A Comparative Analysis of Effectiveness. <i>Clinical Genitourinary Cancer</i> , 2021, 19, 230-236.	0.9	53
6	First experience and clinical results using a new non-coplanar mono-isocenter technique (HyperArc <sup>®</sup> ) for Linac-based VMAT radiosurgery in brain metastases. <i>Journal of Cancer Research and Clinical Oncology</i> , 2019, 145, 193-200.	1.2	50
7	Radiotherapy in patients with connective tissue diseases. <i>Lancet Oncology</i> , The, 2016, 17, e109-e117.	5.1	42
8	Extreme hypofractionation for early prostate cancer: Biology meets technology. <i>Cancer Treatment Reviews</i> , 2016, 50, 48-60.	3.4	40
9	Linac-based radiosurgery for multiple brain metastases: Comparison between two mono-isocenter techniques with multiple non-coplanar arcs. <i>Radiotherapy and Oncology</i> , 2019, 132, 70-78.	0.3	40
10	Volumetric-modulated arc stereotactic body radiotherapy for prostate cancer: dosimetric impact of an increased near-maximum target dose and of a rectal spacer. <i>British Journal of Radiology</i> , 2015, 88, 20140736.	1.0	38
11	Spinal metastases: Is stereotactic body radiation therapy supported by evidences?. <i>Critical Reviews in Oncology/Hematology</i> , 2016, 98, 147-158.	2.0	37
12	Moderate Hypofractionated Postprostatectomy Volumetric Modulated Arc Therapy With Daily Image Guidance (VMAT-IGRT): A Mono-institutional Report on Feasibility and Acute Toxicity. <i>Clinical Genitourinary Cancer</i> , 2017, 15, e667-e673.	0.9	35
13	Modern radiotherapy in cancer treatment during pregnancy. <i>Critical Reviews in Oncology/Hematology</i> , 2019, 136, 13-19.	2.0	33
14	Weekly Cisplatin and Volumetric-Modulated Arc Therapy With Simultaneous Integrated Boost for Radical Treatment of Advanced Cervical Cancer in Elderly Patients: Feasibility and Clinical Preliminary Results. <i>Technology in Cancer Research and Treatment</i> , 2017, 16, 310-315.	0.8	32
15	Phase III study of accelerated Linac-based SBRT in five consecutive fractions for localized prostate cancer. <i>Strahlentherapie Und Onkologie</i> , 2019, 195, 113-120.	1.0	32
16	Available evidence on re-irradiation with stereotactic ablative radiotherapy following high-dose previous thoracic radiotherapy for lung malignancies. <i>Cancer Treatment Reviews</i> , 2015, 41, 511-518.	3.4	31
17	A comparison of swallowing dysfunction after three-dimensional conformal and intensity-modulated radiotherapy. <i>Strahlentherapie Und Onkologie</i> , 2017, 193, 877-889.	1.0	31
18	Preoperative radiotherapy: A paradigm shift in the treatment of breast cancer? A review of literature. <i>Critical Reviews in Oncology/Hematology</i> , 2019, 141, 102-111.	2.0	31

#	ARTICLE	IF	CITATIONS
19	Oligometastasis and local ablation in the era of systemic targeted and immunotherapy. <i>Radiation Oncology</i> , 2020, 15, 92.	1.2	31
20	Daily dosimetric variation between image-guided volumetric modulated arc radiotherapy and MR-guided daily adaptive radiotherapy for prostate cancer stereotactic body radiotherapy. <i>Acta Oncologica</i> , 2021, 60, 215-221.	0.8	31
21	Impact of 18F-Choline PET/CT in the Decision-Making Strategy of Treatment Volumes in Definitive Prostate Cancer Volumetric Modulated Radiation Therapy. <i>Clinical Nuclear Medicine</i> , 2015, 40, e496-e500.	0.7	30
22	Radiation dose intensification in pre-operative chemo-radiotherapy for locally advanced rectal cancer. <i>Clinical and Translational Oncology</i> , 2017, 19, 189-196.	1.2	30
23	Synchronous bilateral breast cancer irradiation: clinical and dosimetric issues using volumetric modulated arc therapy and simultaneous integrated boost. <i>Radiologia Medica</i> , 2017, 122, 464-471.	4.7	30
24	Linac-based stereotactic body radiation therapy for unresectable locally advanced pancreatic cancer: risk-adapted dose prescription and image-guided delivery. <i>Strahlentherapie Und Onkologie</i> , 2018, 194, 835-842.	1.0	30
25	Impact of hydrogel peri-rectal spacer insertion on prostate gland intra-fraction motion during 1.5T MR-guided stereotactic body radiotherapy. <i>Radiation Oncology</i> , 2020, 15, 178.	1.2	30
26	Intensity modulated radiation therapy with simultaneous integrated boost in early breast cancer irradiation. Report of feasibility and preliminary toxicity. <i>Cancer Radiotherapie: Journal De La Societe Francaise De Radiotherapie Oncologique</i> , 2015, 19, 289-294.	0.6	29
27	Recurrence pattern of stereotactic body radiotherapy in oligometastatic prostate cancer: a multi-institutional analysis. <i>Strahlentherapie Und Onkologie</i> , 2020, 196, 213-221.	1.0	29
28	Stereotactic body radiotherapy for lung oligometastases impacts on systemic treatment-free survival: a cohort study. <i>Medical Oncology</i> , 2018, 35, 121.	1.2	28
29	Role of Radiosurgery/Stereotactic Radiotherapy in Oligometastatic Disease: Brain Oligometastases. <i>Frontiers in Oncology</i> , 2019, 9, 206.	1.3	28
30	A comparative analysis between radiation dose intensification and conventional fractionation in neoadjuvant locally advanced rectal cancer: a monocentric prospective observational study. <i>Radiologia Medica</i> , 2020, 125, 990-998.	4.7	28
31	Rectal spacer hydrogel in 1.5T MR-guided and daily adapted SBRT for prostate cancer: dosimetric analysis and preliminary patient-reported outcomes. <i>British Journal of Radiology</i> , 2021, 94, 20200848.	1.0	28
32	Stereotactic radiosurgery for intracranial metastases: linac-based and gamma-dedicated unit approach. <i>Expert Review of Anticancer Therapy</i> , 2016, 16, 731-740.	1.1	27
33	Linac-based radiosurgery or fractionated stereotactic radiotherapy with flattening filter-free volumetric modulated arc therapy in elderly patients. <i>Strahlentherapie Und Onkologie</i> , 2019, 195, 218-225.	1.0	27
34	Hypofractionated radiotherapy in pancreatic cancer: Lessons from the past in the era of stereotactic body radiation therapy. <i>Critical Reviews in Oncology/Hematology</i> , 2016, 103, 49-61.	2.0	26
35	Predictors of mucositis in oropharyngeal and oral cavity cancer in patients treated with volumetric modulated radiation treatment: A dose-volume analysis. <i>Head and Neck</i> , 2016, 38, E815-9.	0.9	26
36	Moderate versus extreme hypofractionated radiotherapy: a toxicity comparative analysis in low- and favorable intermediate-risk prostate cancer patients. <i>Journal of Cancer Research and Clinical Oncology</i> , 2019, 145, 2547-2554.	1.2	26

#	ARTICLE	IF	CITATIONS
37	Radiomic analysis to predict local response in locally advanced pancreatic cancer treated with stereotactic body radiation therapy. <i>Radiologia Medica</i> , 2022, 127, 100-107.	4.7	26
38	Whole brain radiotherapy with hippocampal avoidance and simultaneous integrated boost for brain metastases: a dosimetric volumetric-modulated arc therapy study. <i>Radiologia Medica</i> , 2016, 121, 60-69.	4.7	25
39	Prognostic value of two geriatric screening tools in a cohort of older patients with early stage Non-Small Cell Lung Cancer treated with hypofractionated stereotactic radiotherapy. <i>Journal of Geriatric Oncology</i> , 2020, 11, 475-481.	0.5	25
40	Feasibility and safety of 1.5ÂT MR-guided and daily adapted abdominal-pelvic SBRT for elderly cancer patients: geriatric assessment tools and preliminary patient-reported outcomes. <i>Journal of Cancer Research and Clinical Oncology</i> , 2020, 146, 2379-2397.	1.2	25
41	Intensity-modulated radiotherapy and hypofractionated volumetric modulated arc therapy for elderly patients with breast cancer: comparison of acute and late toxicities. <i>Radiologia Medica</i> , 2019, 124, 309-314.	4.7	23
42	Could 68-Ga PSMA PET/CT become a new tool in the decision-making strategy of prostate cancer patients with biochemical recurrence of PSA after radical prostatectomy? A preliminary, monocentric series. <i>Radiologia Medica</i> , 2018, 123, 719-725.	4.7	22
43	Repeated stereotactic radiosurgery (SRS) using a non-coplanar mono-isocenter (HyperArc <sup>®</sup> , <sup>©</sup> ) technique versus upfront whole-brain radiotherapy (WBRT): a matched-pair analysis. <i>Clinical and Experimental Metastasis</i> , 2020, 37, 77-83.	1.7	22
44	Disease course of lung oligometastatic colorectal cancer treated with stereotactic body radiotherapy. <i>Strahlentherapie Und Onkologie</i> , 2020, 196, 813-820.	1.0	22
45	An update on radiation therapy in head and neck cancers. <i>Expert Review of Anticancer Therapy</i> , 2018, 18, 359-364.	1.1	21
46	Stereotactic body radiotherapy (SBRT) can delay polymetastatic conversion in patients affected by liver oligometastases. <i>Journal of Cancer Research and Clinical Oncology</i> , 2020, 146, 2351-2358.	1.2	21
47	MR-Guided Hypofractionated Radiotherapy: Current Emerging Data and Promising Perspectives for Localized Prostate Cancer. <i>Cancers</i> , 2021, 13, 1791.	1.7	21
48	Three-dimensional conformal versus intensity modulated radiotherapy in breast cancer treatment: is necessary a medical reversal?. <i>Radiologia Medica</i> , 2017, 122, 146-153.	4.7	19
49	(68Ga)-PSMA-PET/CT for the detection of postoperative prostate cancer recurrence: Possible implications on treatment volumes for radiation therapy. <i>Cancer Radiotherapie: Journal De La Societe Francaise De Radiotherapie Oncologique</i> , 2019, 23, 194-200.	0.6	19
50	New metabolic tracers for detectable PSA levels in the post-prostatectomy setting: is the era of melting glaciers upcoming?. <i>Translational Andrology and Urology</i> , 2019, 8, S538-S541.	0.6	19
51	Adaptive SBRT by 1.5ÂT MR-linac for prostate cancer: On the accuracy of dose delivery in view of the prolonged session time. <i>Physica Medica</i> , 2020, 80, 34-41.	0.4	19
52	Stereotactic body radiotherapy for oligometastatic castration sensitive prostate cancer using 1.5ÂT MRI-Linac: preliminary data on feasibility and acute patient-reported outcomes. <i>Radiologia Medica</i> , 2021, 126, 989-997.	4.7	19
53	Comorbidities and intensity-modulated radiotherapy with simultaneous integrated boost in elderly breast cancer patients. <i>Aging Clinical and Experimental Research</i> , 2018, 30, 533-538.	1.4	18
54	Organ sparing and clinical outcome with step-and-shoot IMRT for head and neck cancer: a mono-institutional experience. <i>Radiologia Medica</i> , 2015, 120, 753-758.	4.7	17

#	ARTICLE	IF	CITATIONS
55	Stereotactic ablative radiation therapy for brain metastases with volumetric modulated arc therapy and flattening filter free delivery: feasibility and early clinical results. <i>Radiologia Medica</i> , 2017, 122, 676-682.	4.7	17
56	Hypo-fractionated stereotactic radiation therapy for lung malignancies by means of helical tomotherapy: report of feasibility by a single-center experience. <i>Radiologia Medica</i> , 2018, 123, 406-414.	4.7	17
57	Feasibility and preliminary clinical results of linac-based Stereotactic Body Radiotherapy for spinal metastases using a dedicated contouring and planning system. <i>Radiation Oncology</i> , 2019, 14, 184.	1.2	17
58	Stereotactic Ablative Radiation Therapy for Lung Oligometastases: Predictive Parameters of Early Response by 18 FDG-PET/CT. <i>Journal of Thoracic Oncology</i> , 2017, 12, 547-555.	0.5	16
59	18F-Fluorodeoxyglucose-PET/CT in locally advanced head and neck cancer can influence the stage migration and nodal radiation treatment volumes. <i>Radiologia Medica</i> , 2017, 122, 952-959.	4.7	16
60	Stereotactic body radiation therapy for liver oligometastases: predictive factors of local response by <sup>18</sup> F-FDG-PET/CT. <i>British Journal of Radiology</i> , 2018, 91, 20180058.	1.0	16
61	Automated Planning for Prostate Stereotactic Body Radiation Therapy on the 1.5 T MR-Linac. <i>Advances in Radiation Oncology</i> , 2022, 7, 100865.	0.6	16
62	Cone-beam computed tomography in lung stereotactic ablative radiation therapy: predictive parameters of early response. <i>British Journal of Radiology</i> , 2016, 89, 20160146.	1.0	15
63	What is the role of postoperative re-irradiation in recurrent and second primary squamous cell cancer of head and neck? A literature review according to PICO criteria. <i>Critical Reviews in Oncology/Hematology</i> , 2017, 111, 20-30.	2.0	15
64	Radiotherapy in patients with HIV: current issues and review of the literature. <i>Lancet Oncology</i> , The, 2017, 18, e379-e393.	5.1	15
65	Linac-based SBRT as a feasible salvage option for local recurrences in previously irradiated prostate cancer. <i>Strahlentherapie Und Onkologie</i> , 2020, 196, 628-636.	1.0	15
66	Stereotactic Ablative radiation therapy (SABR) for cardiac arrhythmia: A new therapeutic option?. <i>Radiologia Medica</i> , 2021, 126, 155-162.	4.7	15
67	Mitigation on bowel loops daily variations by 1.5-T MR-guided daily-adaptive SBRT for abdomino-pelvic lymph-nodal oligometastases. <i>Journal of Cancer Research and Clinical Oncology</i> , 2021, 147, 3269-3277.	1.2	15
68	Personalized "Not Omitted" Radiation Oncology for Breast Cancer. <i>Journal of Clinical Oncology</i> , 2015, 33, 4313-4314.	0.8	14
69	Stereotactic body radiotherapy for lung oligometastases: Literature review according to PICO criteria. <i>Tumori</i> , 2018, 104, 148-156.	0.6	14
70	Stereotactic body radiotherapy of central lung malignancies using a simultaneous integrated protection approach. <i>Strahlentherapie Und Onkologie</i> , 2019, 195, 719-724.	1.0	14
71	Stereotactic ablative radiation therapy in renal cell carcinoma: From oligometastatic to localized disease. <i>Critical Reviews in Oncology/Hematology</i> , 2017, 117, 48-56.	2.0	12
72	Stage-I small cell lung cancer: A new potential option for stereotactic ablative radiation therapy? A review of literature. <i>Critical Reviews in Oncology/Hematology</i> , 2017, 112, 67-71.	2.0	11

#	ARTICLE	IF	CITATIONS
73	Prostate re-irradiation: current concerns and future perspectives. Expert Review of Anticancer Therapy, 2020, 20, 947-956.	1.1	11
74	Moderate hypofractionation and simultaneous integrated boost by helical tomotherapy in prostate cancer: monoinstitutional report of acute tolerability assessment with different toxicity scales. Radiologia Medica, 2015, 120, 1170-1176.	4.7	10
75	Fentanyl pectin nasal spray for painful mucositis in head and neck cancers during intensity-modulated radiation therapy with or without chemotherapy. Clinical and Translational Oncology, 2017, 19, 593-598.	1.2	10
76	Combination of novel systemic agents and radiotherapy for solid tumors – Part II: An AIRO (Italian) Tj ETQq0 0 0 rgBT /Overlock 10 Tf Reviews in Oncology/Hematology, 2019, 134, 104-119.	2.0	10
77	Letter. Neurosurgery, 2015, 77, E310.	0.6	9
78	Regarding Ening et al. Charlson comorbidity index: an additional prognostic parameter for preoperative glioblastoma patient stratification. Journal of Cancer Research and Clinical Oncology, 2015, 141, 1139-1140.	1.2	9
79	Dosimetrics of intracranial stereotactic radiosurgery. Strahlentherapie Und Onkologie, 2015, 191, 810-811.	1.0	9
80	Volumetric-modulated arc therapy with vaginal cuff simultaneous integrated boost as an alternative to brachytherapy in adjuvant irradiation for endometrial cancer: a prospective study. Anticancer Research, 2015, 35, 2149-55.	0.5	9
81	Low-Dose Bath with Volumetric Modulated arc Therapy in Breast Cancer: “Much ado about Nothing?” Tumori, 2016, 102, 335-336.	0.6	8
82	Hippocampal dose during Linac-based stereotactic radiotherapy for brain metastases: An observational study. Physica Medica, 2018, 49, 135-138.	0.4	8
83	Moderate hypofractionated helical tomotherapy for localized prostate cancer: preliminary report of an observational prospective study. Tumori, 2019, 105, 516-523.	0.6	8
84	Post-HIFU locally relapsed prostate cancer: high-dose salvage radiotherapy guided by molecular imaging. Radiologia Medica, 2020, 125, 491-499.	4.7	8
85	SBRT for elderly oligometastatic patients as a feasible, safe and effective treatment opportunity. Clinical and Experimental Metastasis, 2021, 38, 475-481.	1.7	8
86	Increased efficacy of stereotactic ablative radiation therapy after bevacizumab in lung oligometastases from colon cancer. Tumori, 2018, 104, 423-428.	0.6	7
87	Combination of novel systemic agents and radiotherapy for solid tumors – part I: An AIRO (Italian) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf Reviews in Oncology/Hematology, 2019, 134, 87-103.	2.0	7
88	Upfront metastasis-directed therapy in oligorecurrent prostate cancer does not decrease the time from initiation of androgen deprivation therapy to castration resistance. Medical Oncology, 2021, 38, 72.	1.2	6
89	Reduction of inter-observer differences in the delineation of the target in spinal metastases SBRT using an automatic contouring dedicated system. Radiation Oncology, 2021, 16, 197.	1.2	6
90	Dose-escalated pelvic radiotherapy for prostate cancer in definitive or postoperative setting. Radiologia Medica, 2021, , 1.	4.7	6

#	ARTICLE	IF	CITATIONS
91	Radiation Dose-Response Relationship for Risk of Coronary Heart Disease in Survivors of Hodgkin Lymphoma. <i>Journal of Clinical Oncology</i> , 2016, 34, 2940-2941.	0.8	5
92	Radiotherapy for the treatment of solitary plasmacytoma: 7-year outcomes by a mono-institutional experience. <i>Journal of Cancer Research and Clinical Oncology</i> , 2021, 147, 1773-1779.	1.2	5
93	Consolidative local therapy in oligometastatic patients. <i>Lancet Oncology</i> , The, 2017, 18, e60.	5.1	4
94	Can thoracic nodes oligometastases be safely treated with image guided hypofractionated radiation therapy?. <i>British Journal of Radiology</i> , 2019, 92, 20181026.	1.0	4
95	What is the role of reirradiation in the management of locoregionally relapsed non small-cell lung cancer?. <i>Lung Cancer</i> , 2020, 146, 263-275.	0.9	4
96	Mammary Chain Irradiation in Left-Sided Breast Cancer: Can We Reduce the Risk of Secondary Cancer and Ischaemic Heart Disease with Modern Intensity-Modulated Radiotherapy Techniques?. <i>Breast Care</i> , 2021, 16, 358-367.	0.8	4
97	The role of radiotherapy in patients with solid tumours after solid organ transplantation: a systematic review. <i>Lancet Oncology</i> , The, 2021, 22, e93-e104.	5.1	4
98	OLIGO-AIRO: a national survey on the role of radiation oncologist in the management of OLIGO-metastatic patients on the behalf of AIRO. <i>Medical Oncology</i> , 2021, 38, 48.	1.2	4
99	PSMA-guided metastases directed therapy for bone castration sensitive oligometastatic prostate cancer: a multi-institutional study. <i>Clinical and Experimental Metastasis</i> , 2022, 39, 443.	1.7	4
100	Nasal Cavity Reirradiation: A Challenging Case for Comparison between Proton Therapy and Volumetric Modulated arc Therapy. <i>Tumori</i> , 2016, 102, S12-S15.	0.6	3
101	Dose prescription in SBRT for early-stage non-small cell lung cancer: are we all speaking the same language?. <i>Tumori</i> , 2021, 107, 030089162092942.	0.6	3
102	Impact of hydrogel peri-rectal spacer insertion on seminal vesicles intrafraction motion during 1.5â€T-MRI-guided adaptive stereotactic body radiotherapy for localized prostate cancer. <i>British Journal of Radiology</i> , 2021, 94, 20210521.	1.0	3
103	Postoperative moderately hypofractionated radiotherapy in prostate cancer: a mono-institutional propensity-score-matching analysis between adjuvant and early-salvage radiotherapy. <i>Radiologia Medica</i> , 2022, , 1.	4.7	3
104	Stereotactic body radiotherapy for pulmonary oligometastases: a monoinstitutional analysis of clinical outcomes and potential prognostic factors. <i>Strahlentherapie Und Onkologie</i> , 2022, 198, 934-939.	1.0	3
105	In Regard to Boero etÂal. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 95, 855-856.	0.4	2
106	Re: Patrick C. Walsh, Nathan Lawrentschuk. Immediate Adjuvant Radiation Therapy Following Radical Prostatectomy Should Not Be Advised for Men with Extraprostatic Extension Who Have Negative Surgical Margins. <i>Eur Urol</i> 2016;69:191â€2. <i>European Urology</i> , 2016, 70, e160-e161.	0.9	2
107	A Plethora of Therapeutic Opportunities for Elderly Patients With Cancer: A Nontrivial Choice. <i>Journal of Clinical Oncology</i> , 2016, 34, 1963-1964.	0.8	2
108	Sequential Boost in Neoadjuvant Irradiation for T3N0-1 Rectal Cancer: Long-Term Results from a Single-Center Experience. <i>Tumori</i> , 2016, 102, 316-322.	0.6	2

#	ARTICLE	IF	CITATIONS
109	Cachexia in Radiotherapy-Treated Patients With Head and Neck Cancer. <i>JAMA Oncology</i> , 2016, 2, 831.	3.4	2
110	Re: Giorgio Gandaglia, Alberto Briganti, Noel Clarke, et al. Adjuvant and Salvage Radiotherapy after Radical Prostatectomy in Prostate Cancer Patients. <i>Eur Urol</i> . In press. <a href="http://dx.doi.org/10.1016/j.eururo.2017.01.039">http://dx.doi.org/10.1016/j.eururo.2017.01.039</a> . <i>European Urology</i> , 2017, 72, e39-e40.	0.9	2
111	Surprising Complete Response of Intramedullary Spinal Cord Metastasis from Breast Cancer: A Case Report and Literature Review. <i>Tumori</i> , 2017, 103, S28-S30.	0.6	2
112	Patient-Reported Outcomes After Swallowing (SWOARs)-Sparing IMRT in Head and Neck Cancers: Primary Results from a Prospective Study Endorsed by the Head and Neck Study Group (HNSG) of the Italian Association of Radiotherapy and Clinical Oncology (AIRO). <i>Dysphagia</i> , 2023, 38, 159-170.	1.0	2
113	In Regard to Arvola et al. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 93, 217-218.	0.4	1
114	Watch-and-wait versus surgical resection for patients with rectal cancer. <i>Lancet Oncology</i> , The, 2016, 17, e133-e134.	5.1	1
115	In reply to Simcock et al.. <i>Clinical and Translational Radiation Oncology</i> , 2020, 23, 65.	0.9	1
116	The use of SBRT in the management of oligometastatic gynecological cancer: report of promising results in terms of tolerability and clinical outcomes. <i>Journal of Cancer Research and Clinical Oncology</i> , 2021, 147, 3613-3618.	1.2	1
117	Capecitabine in combination with oxaliplatin as first-line therapy for advanced gastric cancer: a case report. <i>Tumori</i> , 2011, 97, 115-8.	0.6	1
118	In Regard to Chung et al. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 93, 941-942.	0.4	0
119	Re: Daniel E. Spratt, Hebert A. Vargas, Zachary S. Zumsteg, et al. Patterns of Lymph Node Failure after Dose-escalated Radiotherapy: Implications for Extended Pelvic Lymph Node Coverage. <i>Eur Urol</i> 2017;71:37-43. <i>European Urology</i> , 2017, 71, e121-e122.	0.9	0
120	From chemotherapy to target therapies associated with radiation in the treatment of NSCLC: a durable marriage?. <i>Expert Review of Anticancer Therapy</i> , 2017, 17, 157-165.	1.1	0
121	Stereotactic precision and conventional radiotherapy evaluation (SPACE)-Trial for medically inoperable Stage I NSCLC: A lost opportunity?. <i>Radiotherapy and Oncology</i> , 2017, 122, 319.	0.3	0
122	Induction chemotherapy for nasopharyngeal cancer: An eternally unfinished issue?. <i>European Journal of Cancer</i> , 2017, 82, 153-154.	1.3	0
123	Reply to "Comment on "Efficacy of stereotactic body radiotherapy in oligorecurrent and in oligoprogressive prostate cancer: new evidence from a multicentric study". <i>British Journal of Cancer</i> , 2018, 118, e2-e2.	2.9	0
124	Sparing of swallowing-related organs in radiotherapy for oropharyngeal squamous cell carcinoma. <i>Lancet Oncology</i> , The, 2019, 20, e611.	5.1	0
125	Multimodality imaging for early assessment of head and neck patients during induction chemotherapy: a reliable future option?. <i>Translational Cancer Research</i> , 2016, 5, S405-S407.	0.4	0
126	Using Imaging to Design Dose Volume Constraints for Target and Normal Tissue to Reduce Toxicity. , 2019, , 75-83.		0